Yazarlar : Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC

Yayın : Blood.

Yayın Yılı : 2014

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/24802773

Konu : Diğer

Literatür İçeriği :  Immune thrombocytopenia (ITP) is a disease that results from platelet destruction and production suppression. Eltrombopag belongs to a new class of thrombopoietin mimetic drugs that raise platelet counts in patients with ITP. We performed a single-arm study to assess the response to a single course of dexamethasone (40 mg PO, days 1-4) in combination with eltrombopag (50 mg, days 5-32) in twelve adults with newly diagnosed ITP in an outpatient setting. Median follow-up was 12.5 months. After therapy, day 33, 100% of patients achieved at least ≥30×10⁹/L platelets. Four patients relapsed. Complete response at 6 months (platelets ≥100×10⁹/L) was achieved in 50% of patients and response at 6 months (platelets ≥30<100×10⁹/L) was achieved in other 25%; relapse-free survival was 66.7% at 12 months, with a median response duration of 8.3 months. In conclusion, eltrombopag/dexamethasone is a feasible frontline therapy for ITP. This trial is registered at www.clinicaltrials.gov, identifier: NCT01652599.

Literatür Arşivi